Marc Beer and his new startup company called Renovia, announced that after recently doing a $32 million Series B round, they will continue several new products that have to do with pelvic floor disorders.
The medical technology company, based in Boston, has created many different kinds of products to help people with such symptoms of pelvic disorders as urinary incontinence. 250 million women around the world have to deal with urinary incontinence. Renovia did recently get FDA approval of their first product called Leva.
What helped Renovia get through the Series B round is Longwood Fun, a medical care- investing firm. A Ascension Ventures company from Missouri and Perceptive Advisors from New York also helped Renovia get through this round. Funding the creation and testing of more diagnostic and therapeutic products including a new version of Leva came from the above companies.
Marc Beer, the CEO of Renovia, is excited by the support that he gets from medical care investors who have the same vision that he and his company of. They all want to improve the lives of millions of women that have to deal with pelvic disorders. His combines proprietary and innovative sensor technologies and form factors with a virtual health platform that inform their customers about treatment options. This should hopefully lead to more knowledge and understanding about pelvic disorders and should lead to cheaper long-term healthcare costs.
Marc Beer is 52 years old and Renovia is not the only company that he founded. He also founded Good Start Genetics.
He does have some spare time to be a member of other organizations that have nothing to do with his day job. He has been a part of Notre Dame Research Advisory and Notre Dame Research and Communications Advisory Committee.
Marc Beer attended Miami University (Ohio) and got a Bachelor of Science degree. It is not known for some reason what his major was at this university.
The first company that he was known to have founded was ViaCell. He founded it in April of 2000. This biotech firm focused on collecting, preserving and developing umbilical cord blood. When he left this organization, it had become a robust organization that would continue to thrive and grow into the future. By the time it was bought in 2007 by Perkin Elmer, it had 300 employees. It is hoped that he has the same success with his current company. Learn more: https://www.linkedin.com/in/marcbeer